Apply for Ofev (Nintedanib) Copay Assistance & Patient Savings

Ofev copay assistance refers to financial support programs — such as manufacturer copay cards, patient assistance programs, and nonprofit foundation grants — that help reduce the out-of-pocket cost of Ofev (nintedanib) for eligible patients. QuickRx Specialty Pharmacy provides free enrollment support to help you identify and apply for programs you may qualify for based on your insurance and financial situation. Our patient navigators handle all paperwork so you can focus on your treatment.

Eligibility for Ofev copay assistance varies by program. Manufacturer copay card programs are generally available to patients with commercial (private) insurance. Patient assistance programs are typically available to patients who are uninsured, underinsured, or whose government insurance (such as Medicare or Medicaid) does not cover the copay card benefit.

Because a generic version of nintedanib is also available, additional savings options may exist that are not tied to the brand-name Ofev program. QuickRx evaluates your specific situation to identify the programs you are most likely to qualify for at no cost to you. Call (917) 830-2525 to speak with a patient navigator.

No. QuickRx Specialty Pharmacy provides copay assistance enrollment support as a completely free service. There are no fees, no hidden charges, and no obligation. Our patient navigator team assists with your Ofev application because we believe cost should never be a barrier to pulmonary fibrosis treatment.

What QuickRx Does For Free:

• Reviews your insurance coverage and identifies all available programs
• Evaluates both brand Ofev and generic nintedanib savings options
• Completes copay card and patient assistance applications on your behalf
• Coordinates with your healthcare provider for required documentation
• Manages ongoing renewals and insurance changes
• Provides continuous support throughout your Ofev treatment

Yes. Generic nintedanib is available in the United States, which may offer a lower-cost alternative to brand-name Ofev for eligible patients. Generic nintedanib contains the same active ingredient (nintedanib esylate) at the same dosage strengths (100 mg and 150 mg capsules) as brand-name Ofev.

Whether brand Ofev or generic nintedanib is most appropriate depends on your insurance formulary, your prescriber’s preference, and your specific clinical situation. QuickRx patient navigators can help you understand your options and identify the best savings programs available for both the brand and generic. Call (917) 830-2525 for a free benefits review.

Medicare patients cannot use manufacturer copay cards due to federal regulations. However, other financial assistance options may still be available for Ofev or generic nintedanib.

Options for Medicare Patients:

• Patient assistance programs: May provide Ofev at reduced or no cost for qualifying patients
• Generic nintedanib: May be covered at a lower cost tier under your Medicare Part D plan
• Pulmonary fibrosis foundation grants: Nonprofit organizations focused on IPF and ILD may offer financial assistance regardless of insurance type
• Medicare Extra Help / Low-Income Subsidy: May help with specialty drug costs for qualifying patients
• State pharmaceutical assistance programs: Varies by state

QuickRx patient navigators can review your specific Medicare coverage and identify all available options at no cost to you.

Ofev (nintedanib) is an oral prescription medication approved by the FDA for three related lung conditions in adults:

FDA-Approved Indications for Ofev:

• Idiopathic pulmonary fibrosis (IPF): A chronic, progressive scarring of the lung tissue with no known cause. Ofev slows the rate of decline in lung function in adults with IPF.
• Progressive pulmonary fibrosis (PPF): Ofev is indicated for chronic progressive fibrosing interstitial lung diseases (ILDs) — a broad category covering ILDs of various causes that continue to worsen despite treatment. This includes ILD associated with conditions such as rheumatoid arthritis, sarcoidosis, and hypersensitivity pneumonitis.
• Systemic sclerosis–associated interstitial lung disease (SSc-ILD): Ofev is indicated to slow the rate of decline in pulmonary function in patients with ILD associated with systemic sclerosis (scleroderma).

Ofev is not a cure for any of these conditions and does not reverse existing scar tissue — it works by slowing disease progression and preserving lung function over time.

Ofev (nintedanib) is taken orally as a capsule, twice daily approximately 12 hours apart.

Ofev Dosing Information:

• Standard dose (no liver impairment): 150 mg orally every 12 hours with food. Maximum dose: 300 mg per day.
• Reduced dose (mild hepatic impairment, Child-Pugh A): 100 mg every 12 hours with food
• Moderate to severe hepatic impairment: Ofev is not recommended
• If a dose is missed, skip it and take the next dose at the regularly scheduled time — do not double up

Important Administration Notes:

• Swallow capsules whole with liquid — do not open, chew, or crush (the contents are bitter and can cause irritation)
• If you accidentally come into contact with capsule contents, wash your hands immediately and thoroughly
• Patients who smoke should stop smoking before starting Ofev — smoking reduces Ofev exposure by approximately 21%

Always follow your healthcare provider’s specific dosing instructions.

The most commonly reported side effect of Ofev is diarrhea, which occurs in the majority of patients. Most GI side effects are mild to moderate in intensity and typically occur within the first 3 months of treatment.

Common Ofev Side Effects (>10%):

• Diarrhea (62% to 76% of patients) — the most frequent side effect
• Nausea (24% to 32%)
• Vomiting (12% to 25%)
• Abdominal pain (15% to 18%)
• Decreased appetite (9% to 11%)
• Weight loss (10% to 12%)
• Increased liver enzymes (13% to 14%)
• Fatigue (10% to 11%)
• Nasopharyngitis (13%)

Patients are often advised to have an anti-diarrheal medication such as loperamide (Imodium) available at all times while taking Ofev, and to maintain adequate hydration. Talk to your healthcare provider about any side effects that concern you.

Yes. Ofev carries important warnings that patients should discuss with their prescriber before and during treatment.

Important Ofev Warnings:

• Liver toxicity: Serious cases of drug-induced liver injury, including cases with fatal outcomes, have been reported. Liver function tests (ALT, AST, bilirubin) are required before starting Ofev and regularly during the first 3 months of treatment. Risk may be higher in women, patients weighing less than 65 kg, Asian patients, and older patients.
• Diarrhea: Severe diarrhea can lead to life-threatening dehydration if not managed promptly. Patients should contact their doctor immediately if diarrhea is severe or persistent.
• Bleeding: Ofev may increase the risk of bleeding, including serious and potentially fatal bleeding events. Use with caution in patients at risk for bleeding or taking anticoagulants.
• Arterial thromboembolic events: Events including myocardial infarction (heart attack) have been reported. Use with caution in patients with known cardiovascular risk factors.
• GI perforation: Rare cases of gastrointestinal perforation, some fatal, have been reported. Use with caution in patients with recent abdominal surgery, diverticular disease, or taking NSAIDs or corticosteroids.
• Fetal harm: Ofev can cause birth defects or fetal death. Patients who can become pregnant must use highly effective contraception during therapy and for at least 3 months after the last dose.

This information is for educational purposes only. Patients should review all risks with their prescribing healthcare provider before starting Ofev.

Ofev capsules should be stored properly to maintain medication integrity.

Ofev Storage Instructions:

• Store at room temperature between 68°F and 77°F (20°C to 25°C)
• Brief excursions between 59°F and 86°F (15°C and 30°C) are permitted
• Protect from high humidity
• Avoid excessive heat
• Keep in the original container

If you have questions about storing your Ofev, contact your QuickRx pharmacist at (917) 830-2525.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by the buildup of scar tissue (fibrosis) in the lungs with no identifiable cause — “idiopathic” means the origin is unknown. The scarring makes the lungs progressively stiffer and less able to transfer oxygen into the bloodstream, leading to worsening breathlessness over time.

Key Facts About IPF:

• IPF primarily affects adults over 60 years of age
• It is slightly more common in men and in people with a history of smoking
• There is currently no cure for IPF — treatment focuses on slowing disease progression
• Ofev (nintedanib) and pirfenidone are the two FDA-approved medications that slow the rate of lung function decline in IPF
• Common symptoms include progressive shortness of breath, dry cough, fatigue, and in some cases a crackling sound in the lungs when breathing

Patients diagnosed with IPF should work with a pulmonologist experienced in interstitial lung diseases to develop a treatment and monitoring plan.

Progressive pulmonary fibrosis (PPF) describes a pattern of behavior in chronic fibrosing interstitial lung diseases (ILDs) where the lung scarring continues to worsen despite treatment, regardless of the underlying cause of the ILD.

Unlike IPF — which has no known cause — PPF can occur in patients whose ILD is associated with a known condition such as rheumatoid arthritis, sarcoidosis, hypersensitivity pneumonitis, mixed connective tissue disease, or other inflammatory conditions. When these ILDs follow a progressive course and fail to respond to standard therapies, Ofev is indicated to slow further decline in lung function.

Patients with PPF are typically managed by a pulmonologist, often in collaboration with a rheumatologist or other specialist depending on the underlying cause.

Systemic sclerosis–associated interstitial lung disease (SSc-ILD) is a lung complication of systemic sclerosis (scleroderma), a rare autoimmune disease that causes hardening and tightening of the skin and connective tissues throughout the body. When systemic sclerosis affects the lungs, it causes scarring and inflammation of the lung tissue (ILD), which progressively impairs breathing and lung function.

SSc-ILD is one of the leading causes of morbidity and mortality in patients with systemic sclerosis. Ofev is FDA-approved to slow the rate of decline in pulmonary function in patients with SSc-ILD. Patients with this condition are typically managed by both a rheumatologist and a pulmonologist.

If you have systemic sclerosis and have been prescribed Ofev for lung disease, QuickRx patient navigators can help you access copay assistance. Call (917) 830-2525.

Yes. Ofev (nintedanib) has several clinically important drug interactions. Always inform your healthcare provider and pharmacist of all medications, supplements, and herbal products you are taking.

Notable Ofev Drug Interactions:

• Anticoagulants (blood thinners): Concurrent use may increase the risk of bleeding; monitor closely
• Strong CYP3A4 and P-glycoprotein inducers (including rifampin and St. John’s wort): May significantly decrease Ofev blood levels, reducing effectiveness — avoid concurrent use
• Strong CYP3A4 and P-glycoprotein inhibitors: May increase Ofev blood levels, potentially increasing side effects; monitor closely
• NSAIDs (ibuprofen, naproxen, aspirin, etc.): May increase the risk of bruising and bleeding when used with Ofev; consult your doctor before use
• Tobacco (smoking): Smoking reduces Ofev exposure by approximately 21%; patients should stop smoking before and during Ofev therapy
• Letrozole: May increase Ofev blood concentrations; monitor for increased side effects

QuickRx pharmacists perform thorough drug interaction reviews as part of the dispensing process. Call (917) 830-2525 with any questions.

Yes. QuickRx Specialty Pharmacy is licensed to dispense and ship Ofev (nintedanib) and generic nintedanib to patients in all 50 states. We provide free home delivery and ensure medications are shipped properly to maintain integrity.

Why Patients Choose QuickRx for Ofev:

• Nationwide shipping to all 50 states
• Free copay assistance enrollment services for both brand Ofev and generic nintedanib
• Dedicated patient navigators for IPF, progressive pulmonary fibrosis, and SSc-ILD patients
• Prior authorization support and appeal assistance
• URAC- and ACHC-accredited specialty pharmacy
• Personal, one-on-one support from enrollment through ongoing treatment

Call us at (917) 830-2525 or complete the form on this page to get started.

QuickRx is a URAC- and ACHC-accredited specialty pharmacy with a dedicated patient navigator team and hands-on financial support services for patients on high-cost specialty medications like Ofev.

What Sets QuickRx Apart:

• Dedicated patient navigators specializing in pulmonary fibrosis, rare lung disease, and autoimmune conditions
• Savings options evaluated for both brand Ofev AND generic nintedanib
• Free copay card enrollment, patient assistance applications, and foundation grant coordination
• Prior authorization management and appeals support
• Licensed in all 50 states with free home delivery
• URAC- and ACHC-accredited — held to the highest standards in specialty pharmacy

Our goal is to make sure no patient with IPF, progressive pulmonary fibrosis, or SSc-ILD goes without their Ofev due to cost. Complete the form above or call us at (917) 830-2525 to get started today.